TransCode Therapeutics Submits IND Amendment for Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Reuters

02/05

TransCode <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Submits IND Amendment for Phase 2a Trial of TTX-MC138 in Colorectal Cancer

TransCode Therapeutics Inc. announced the submission of an Investigational New Drug $(IND)$ application amendment to the U.S. Food and Drug Administration (FDA) for a planned Phase 2a clinical trial of its lead therapeutic candidate, TTX-MC138. The trial, focused on colorectal cancer patients with positive markers for circulating tumor DNA, will be conducted in collaboration with Quantum Leap Healthcare Collaborative within the PRE-I-SPY program. The Phase 2a trial is expected to enroll up to 45 patients and will be led by Dr. Paula Pohlmann of MD Anderson Cancer Center.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE80377) on February 05, 2026, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2609308909"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609308909\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609308909?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-05 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609308909","market":"fut","top_or_hot":-1,"title":"TransCode Therapeutics Submits IND Amendment for Phase 2a Trial of TTX-MC138 in Colorectal Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Submits IND Amendment for Phase 2a Trial of TTX-MC138 in Colorectal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransCode Therapeutics Inc. announced the submission of an Investigational New Drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> application amendment to the U.S. Food and Drug Administration (FDA) for a planned Phase 2a clinical trial of its lead therapeutic candidate, TTX-MC138. The trial, focused on colorectal cancer patients with positive markers for circulating tumor DNA, will be conducted in collaboration with <a href=\"https://laohu8.com/S/QMCO\">Quantum</a> Leap Healthcare Collaborative within the PRE-I-SPY program. The Phase 2a trial is expected to enroll up to 45 patients and will be led by Dr. Paula Pohlmann of MD Anderson Cancer Center.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE80377) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransCode Therapeutics Submits IND Amendment for Phase 2a Trial of TTX-MC138 in Colorectal Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransCode Therapeutics Submits IND Amendment for Phase 2a Trial of TTX-MC138 in Colorectal Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-05 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Submits IND Amendment for Phase 2a Trial of TTX-MC138 in Colorectal Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransCode Therapeutics Inc. announced the submission of an Investigational New Drug <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> application amendment to the U.S. Food and Drug Administration (FDA) for a planned Phase 2a clinical trial of its lead therapeutic candidate, TTX-MC138. The trial, focused on colorectal cancer patients with positive markers for circulating tumor DNA, will be conducted in collaboration with <a href=\"https://laohu8.com/S/QMCO\">Quantum</a> Leap Healthcare Collaborative within the PRE-I-SPY program. The Phase 2a trial is expected to enroll up to 45 patients and will be led by Dr. Paula Pohlmann of MD Anderson Cancer Center.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE80377) on February 05, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260205:nNDL4wsdsm:1","article_id":"2609308909","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609308909","pubTimestamp":1770296732,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TransCode Therapeutics Inc. announced the submission of an Investigational New Drug  application amendment to the U.S. Food and Drug Administration  for a planned Phase 2a clinical trial of its lead therapeutic candidate, TTX-MC138. The trial, focused on colorectal cancer patients with positive markers for circulating tumor DNA, will be conducted in collaboration with Quantum Leap Healthcare Collaborative within the PRE-I-SPY program. The Phase 2a trial is expected to enroll up to 45 patients and will be led by Dr. Paula Pohlmann of MD Anderson Cancer Center.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on February 05, 2026, a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","RNAZ":"TransCode Therapeutics  Inc.","BK4139":"生物科技"},"translate_title":"TransCode Therapeutics提交TTX-MC138治疗结直肠癌2a期试验IND修正案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAZ":0.9},"content_text":"TransCode Therapeutics Submits IND Amendment for Phase 2a Trial of TTX-MC138 in Colorectal Cancer\n    \n\n        TransCode Therapeutics Inc. announced the submission of an Investigational New Drug $(IND)$ application amendment to the U.S. Food and Drug Administration (FDA) for a planned Phase 2a clinical trial of its lead therapeutic candidate, TTX-MC138. The trial, focused on colorectal cancer patients with positive markers for circulating tumor DNA, will be conducted in collaboration with Quantum Leap Healthcare Collaborative within the PRE-I-SPY program. The Phase 2a trial is expected to enroll up to 45 patients and will be led by Dr. Paula Pohlmann of MD Anderson Cancer Center.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE80377) on February 05, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}